Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LUCD Stock Forecast 2025-2026
$1.03
Current Price
$135.03M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LUCD Price Targets
+676.7%
To High Target of $8.00
+191.3%
To Median Target of $3.00
+142.7%
To Low Target of $2.50
LUCD Price Momentum
-2.8%
1 Week Change
-4.6%
1 Month Change
+22.6%
1 Year Change
+25.6%
Year-to-Date Change
-42.8%
From 52W High of $1.80
+37.3%
From 52W Low of $0.75
📊 TOP ANALYST CALLS
Did LUCD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lucid Diagnostics is one of their latest high-conviction picks.
Latest LUCD Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, LUCD has a bullish consensus with a median price target of $3.00 (ranging from $2.50 to $8.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.03, the median forecast implies a 191.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 676.7% upside. Conversely, the most conservative target is provided by Mark Massaro at BTIG, suggesting a 142.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LUCD Analyst Ratings
5
Buy
0
Hold
0
Sell
LUCD Price Target Range
Low
$2.50
Average
$3.00
High
$8.00
Current: $1.03
Latest LUCD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LUCD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Oct 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.00 |
| Sep 10, 2025 | BTIG | Mark Massaro | Buy | Reiterates | $2.50 |
| Sep 5, 2025 | BTIG | Mark Massaro | Buy | Maintains | $2.50 |
| Aug 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Jul 16, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Jun 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.75 |
| May 15, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $2.00 |
| May 14, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.50 |
| Apr 11, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Mar 26, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $2.00 |
| Mar 24, 2025 | Needham | Mike Matson | Buy | Maintains | $3.00 |
| Dec 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.00 |
| Nov 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $2.00 |
| Nov 14, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.00 |
| Nov 14, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
| Sep 10, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.25 |
| Aug 13, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.00 |
| Aug 13, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
Lucid Diagnostics Inc. (LUCD) Competitors
The following stocks are similar to Lucid Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LUCD
Lucid Diagnostics
mkt cap
135.03M
Lucid Diagnostics Inc. (LUCD) Financial Data
Lucid Diagnostics Inc. has a market capitalization of $135.03M with a P/E ratio of -1.0x. The company generates $4.40M in trailing twelve-month revenue with a -63.3% profit margin.
Revenue growth is +3.3% quarter-over-quarter, while maintaining an operating margin of -971.0% and return on equity of -331.2%.
Valuation Metrics
Market Cap
$135.03M
Enterprise Value
$166.57M
P/E Ratio
-1.0x
PEG Ratio
0.0x
Price/Sales
31.6x
Growth & Margins
Revenue Growth (YoY)
+3.3%
Gross Margin
-40.1%
Operating Margin
-971.0%
Net Margin
-63.3%
EPS Growth
+3.3%
Financial Health
Cash/Price Ratio
+35.8%
Current Ratio
1.9x
Debt/Equity
94.2x
ROE
-331.2%
ROA
-79.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lucid Diagnostics Inc. (LUCD) Business Model
About Lucid Diagnostics Inc.
What They Do
Develops innovative diagnostics for esophageal cancer.
Business Model
The company generates revenue primarily through its flagship product, EsoCheck, which offers a less invasive alternative to traditional endoscopy for diagnosing esophageal conditions. By focusing on early detection and improving patient outcomes, Lucid Diagnostics positions itself as a valuable partner in the healthcare sector, capitalizing on the increasing demand for preventative medical technologies.
Additional Information
Lucid Diagnostics is part of the growing MedTech industry, aligning with trends towards non-invasive diagnostic solutions and preventative healthcare, which enhances its potential for growth and impact in patient care.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
72
CEO
Dr. Lishan Aklog M.D.
Country
United States
IPO Year
2021
Website
www.luciddx.comLucid Diagnostics Inc. (LUCD) Latest News & Analysis
Latest News
Quick Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) has won the GenomeWeb 2025 Best Places to Work award in its size category, recognized among top firms in diagnostics and precision medicine.
Why It Matters
Lucid Diagnostics' recognition as a top workplace enhances its reputation, potentially attracting talent and investors, which could drive future growth and innovation in cancer diagnostics.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Lucid Diagnostics Inc. (LUCD) will hold its Q3 2025 earnings call on November 12, 2025, at 8:30 AM EST, featuring key executives and analysts from various firms.
Why It Matters
Lucid Diagnostics' Q3 2025 earnings call indicates upcoming financial insights and performance metrics that could influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Lucid Diagnostics Inc. (LUCD) reported a quarterly loss of $0.10 per share, worse than the expected loss of $0.06, and an improvement from a loss of $0.20 per share a year prior.
Why It Matters
Lucid Diagnostics' larger-than-expected quarterly loss may signal ongoing challenges, potentially impacting stock performance and investor confidence. Year-over-year improvement could offer some optimism.
Source: Zacks Investment Research
Market Sentiment:
Negative
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
25 days ago
Quick Summary
Lucid Diagnostics reported 3Q25 revenue of $1.2 million from 2,841 EsoGuard® tests and has over $47 million in cash. A Medicare coverage meeting showed unanimous expert support for EsoGuard.
Why It Matters
Lucid Diagnostics' revenue growth and strong cash position extend its financial runway, while unanimous expert support for Medicare coverage could significantly boost future earnings.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PAVmed Inc. launched the commercial phase of a partnership and resumed development of an implantable monitor. It signed an LOI for endoscopic imaging tech. A conference call is scheduled for November 13, 2025.
Why It Matters
PAVmed's partnership and product development activities signal potential growth and innovation, which could positively impact its stock price and attract investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) will participate in the Canaccord Genuity MedTech Forum on November 20, 2025, with CFO Dennis McGrath available for investor meetings.
Why It Matters
Lucid's participation in a prominent healthcare forum and CFO's availability for meetings signal potential growth opportunities and investor engagement, which may influence stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LUCD Stock
What is Lucid Diagnostics Inc.'s (LUCD) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Lucid Diagnostics Inc. (LUCD) has a median price target of $3.00. The highest price target is $8.00 and the lowest is $2.50.
Is LUCD stock a good investment in 2026?
According to current analyst ratings, LUCD has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LUCD stock?
Wall Street analysts predict LUCD stock could reach $3.00 in the next 12 months. This represents a 191.3% increase from the current price of $1.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lucid Diagnostics Inc.'s business model?
The company generates revenue primarily through its flagship product, EsoCheck, which offers a less invasive alternative to traditional endoscopy for diagnosing esophageal conditions. By focusing on early detection and improving patient outcomes, Lucid Diagnostics positions itself as a valuable partner in the healthcare sector, capitalizing on the increasing demand for preventative medical technologies.
What is the highest forecasted price for LUCD Lucid Diagnostics Inc.?
The highest price target for LUCD is $8.00 from Edward Woo at Ascendiant Capital, which represents a 676.7% increase from the current price of $1.03.
What is the lowest forecasted price for LUCD Lucid Diagnostics Inc.?
The lowest price target for LUCD is $2.50 from Mark Massaro at BTIG, which represents a 142.7% increase from the current price of $1.03.
What is the overall LUCD consensus from analysts for Lucid Diagnostics Inc.?
The overall analyst consensus for LUCD is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are LUCD stock price projections?
Stock price projections, including those for Lucid Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:50 PM UTC